with update VKXXXX. recent an program provide now I'll progress lead activity on our Greg. Thanks, and
tissue in receptor available that small from potential the As including the hormone thyroid disorders molecule therapeutic as Nash. possess suggesting well agonist a subtype receptor VKXXXX range of is orally reminder, promising metabolic the a as liver selectivity an of beta
positive disease. we trial XX-week September fatty results of X In from VKXXXX Phase hypercholesterolemia with announced in patients liver a non-alcoholic XXXX, and
well trial this in potent liver plasma in demonstrating its As as reductions we had measures. as endpoints, both lipid content fat discussed, improvements primary secondary successfully achieved and previously
of in average XX% XX%, overall placebo relative proportion from XX% X% for at with liver fat brief receiving least experienced relative a of from to liver The VKXXXX experiencing compared approximately in reminder, patients XX% a median reductions XXX% patients As with approximately fat for placebo. reduction ranging XX% with XX% to compared patients. the ranged
experienced and atherogenic patients compared proteins at In (a). content reduction including in significant addition, apolipoprotein XX% XX% triglycerides, Cholesterol, reductions relative lipids, fat Lipoprotein liver plasma baseline. a such VKXXXX least as in LDL B to and produced also VKXXXX of receiving
This benefit. of long lipid beta is particular of feature NASH setting may the suggest cardiovascular of a term novel is it interest in thyroid receptor lowering activation profile as and
addition In the VKXXXX demonstrated impressive advocacy observed, and to has safety also profile. tolerability encouraging an
distributed X numbers In the patients arms. relatively placebo among and treatment events study, events VKXXXX across were of Phase the no were or reported adverse serious evenly overall receiving adverse
We liver compound Xb into believe study are in we phase targeting its advance effects safety, with cardiovascular apart NASH. competitive pleased to with and a patients confirmed this NASH. from And potential combined programs VKXXXX’s tolerability it benefits, set biopsy specific potent very
us XXXX, to preparation completed with clinical In a for evaluations to and division additional Errors this we FDA study, Products. the of VKXXXX IND Inborn Division new of file several of FDA’s and in preclinical Gastroenterology enable
reminder, was required prior active IND the is division and toward the endocrine in a new IND and products. because hyperlipidemia As directed was a of metabolic
Division GI applications where NASH the reviewed. most IND are However, is
this preparation co-administered included VKXXXX tolerability to the Nash we previously the and confirmed XX-week new completed IND, pharmacokinetics VKXXXX and atorvastatin. XXXX These when during with described X evaluate no in study Phase moment the interaction for several ago. of between study demonstrating the study Phase a reported I a safety, In The studies X results of data, atorvastatin. addition to meaningful
evaluate every of dosed Phase safety, We the previously possesses tolerability and an confirmed in the a day data demonstrating regimen. X to pharmacokinetics VKXXXX reported PK also that study predictable and other results consistent VKXXXX conducted These profile.
of and VKXXXX pharmacodynamics to a X evaluate tolerability, We the under study also regimens. dosing pharmacokinetics safety, Phase conducted various
plasma of XX These humans. support in data demonstrated completed And and that studies we in regimens may dosing alternative measures toxicity lipids. weeks duration produce to also finally, XX dosing in improvements chronic of
of new the work GI IND that this formed the The and was Division. with the results basis of prior filed
NASH the patients to other a day, designed in this will initiation and we filing, every is have Study November, milligram Following and the fibrosis. The study day, of randomized, efficacy, five X controlled patients milligrams it biopsy assess target safety milligrams tolerability XXX daily, of VOYAGE study X.X The enrollment excited other with named confirmed trial, and Study one We've Xb across including double-blind VKXXXX Phase placebo arms, announced placebo. multi treatment patients – milligrams study, VKXXXX underway. approximately in a IND XX NASH. center daily, in we're and to VOYAGE every of in of the with the
in will evaluate magnetic resonance imaging, the as to liver density the baseline from VKXXXX relative The population includes fibrosis. well FX FX fibrosis, target as FX patients of FX enrolment. additional as in endpoint subjects study risk The with fraction, compared possess fat primary assessed treated XX% with patients content to placebo. be and for as proton eligible a with fat by week-XX also to change factors to must up
Secondary changes, biopsy objectives dosing. XX-weeks of include evaluation of by hepatic assessed histologic after
later the patients We at and year. open sites U.S. expect the in are to currently U.S. additional this dosing sites clinical outside
In these Association We look addition, liver to informed XX-week for fourth the to XX. oral the the VKXXXX data meeting additional annual Study were of been this time. has study describing Phase from abstract We of recently VOYAGE prior April sharing EASL. X presentation an European in at additional selected the the of forward on quarter, or we presentation that study for data that submitted the at an commencing the the abstract for
VKXXXX during in the Given compelling a trial demonstrates the X the studies to efficacy on as safety look the the sharing of trial, with positive results that provide from and worldwide potential VOYAGE additional from NASH. suffering We XXXX, continue forward profile, the generated previous believe VKXXXX the we and millions to phase supplemental to data and benefit patients updates Study progresses. to multiple
levels an treatment a adrenoleukodystrophy, motor which cerebral as disease are accumulation program. chain an contribute very is evaluated tissue long in provide acids potential these very treatment. devastating that of The for result is VKXXXX update defect neuron is approved that elevated no on can in chain for caused toxicities long and a acid of now X-ALD disease being severe or VKXXXX characteristic X-linked I'll and peroxisomal called is This believed to defect plasma to ABCDX. there by transporter X-ALD. it in and the is fatty our a the are fatty disease.
bio-receptor of play receptor agonists results long in in and in subtype. expression is small an the selectivity long the very plasma believed in a is fatty chain acids believed chain in increase acid molecule thyroid important Like target have is an VKXXXX, from significant transporter, which intervention compensatory potential a is tissue. that in for studies of and vivo very a To-date, demonstrated result available both results of The beta in a in vitro orally beta for reduction administration VKXXXX to receptor possesses because that X-ALD to role therapeutic metabolism. VKXXXX fatty it
move to this Given these into promising patients to provide results, the we believe X-ALD clinic. program may eager benefit we VKXXXX and with are
conducting currently study are and the for We VKXXXX a humans. file this half expect the followed by to in initiation year, IND first we proof-of-concept IND-enabling work of of in
lead two advancing are in clinical development. programs There
our balance continue carefully sheet. We to manage
As Greg provide we points inflection reported approximately XXXX earlier, reach with to million equivalents. VKXXXX VKXXXX. in cash We clinical ended and ample believe those and runway these multiple resources $XXX with
I'd VKXXXX and VKXXXX. the completed way XXXX like critical work the closing, important potential for that realizing pave in to both In to the reiterate was of
Study. in treatment excited clinic. For phase the for through look we it enrollment of generated development data belief are most the promising VOYAGE advancing validate of both our forward XXXX We our to VKXXXX, in one is be and Xb and continued the candidates that XXXX in the it NASH to compelling today
With respect to proof-of-concept studies during to study half to the of initiate we is humans. in that toward a this It enabling year. the continue allow first goal VKXXXX, will file IND us of the working completion our IND
through for again Operator? like prepared strong, the execute remains the to concludes today. call providing open This for our sheet joining And balance for to I'd creating our Thanks multiple us. resources events. Finally, value comments now questions.
